Triple
T5689061
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | CLARITY AD |
E125383
|
entity |
| Predicate | coSponsor |
P3260
|
FINISHED |
| Object | Biogen |
E3807
|
NE FINISHED |
How this triple was built (2 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Biogen | Statement: [CLARITY AD, coSponsor, Biogen]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Biogen Context triple: [CLARITY AD, coSponsor, Biogen]
-
A.
Biogen
chosen
Biogen is a major American biotechnology company known for developing therapies for neurological and neurodegenerative diseases.
-
B.
Eisai and Biogen
Eisai and Biogen are pharmaceutical companies that collaborate on developing innovative therapies, particularly in the field of neurodegenerative diseases such as Alzheimer’s.
-
C.
Alkermes
Alkermes is a biopharmaceutical company that develops innovative medicines for central nervous system disorders and other serious chronic diseases.
-
D.
Alexion Pharmaceuticals
Alexion Pharmaceuticals is a biopharmaceutical company specializing in the development of therapies for rare and severe diseases, particularly in the field of complement biology.
-
E.
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals is a leading American biotechnology company known for developing innovative antibody-based therapies for serious diseases, including eye disorders, cancer, and inflammatory conditions.
- F. None of above.
- G. Unsure - the case is ambiguous/there is not enough information to decide.
Provenance (3 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69c0082bb19c8190823a4facd3cba79b |
completed | March 22, 2026, 3:18 p.m. |
| NER | Named-entity recognition | batch_69c023e1c6148190aeae7620bd9ee9d4 |
completed | March 22, 2026, 5:16 p.m. |
| NED1 | Entity disambiguation (via context triple) | batch_69c05a47457c8190bc75f11a7f011a8a |
completed | March 22, 2026, 9:08 p.m. |
Created at: March 22, 2026, 3:44 p.m.